BioCaptiva raises over £1m in seed funding from Archangels and Scottish Enterprise to advance cancer detection technology.
The University of Edinburgh spin-out has secured backing to fund its first human trials.
Share allotment filed at Companies House
Biocaptiva is a Scottish medical technology company developing the BioCaptis device to capture cell-free DNA for cancer management.
Edinburgh-based life sciences spin-out BioCaptiva has secured over £1m in seed funding to advance its novel liquid biopsy technology. The round was backed by Archangels and Scottish Enterprise. The capital will enable the company to in-license its core technology and conduct its first human trials. Based on research from the University of Edinburgh, the company has created the BioCollector device to capture circulating free DNA in quantities exceeding standard blood draws.
From the founder
"The BioCollector is a disruptive technology which will be transformational for liquid biopsy testing. We are confident that this platform technology can make a significant impact in this important area and, ultimately, enable cancers to be detected more quickly and accurately, enabling patients to receive precision cancer treatment as early as possible."
Jeremy Wheeler
CEO at Biocaptiva
Investor perspective
"BioCaptiva has the potential to provide pharma companies and clinicians with high levels of cfDNA from individual patients that could revolutionise the way some cancers are detected. This has the potential to vastly increase the sensitivity and applicability of liquid biopsy for detection of cancerous tumours which are often diagnosed too late to enable specific treatment options to improve outcomes"
Sarah Hardy
Head of New Investments and Director, Archangels
Use of funds
- 01Fund research and development
Investors
Categories
About the company
Biocaptiva
Biocaptiva develops technology designed to improve liquid biopsy testing for cancer management.